A. Raschig

Treatment with the Selective Muscarinic Agonist Talsaclidine Decreases Cerebrospinal Fluid Levels of Total Amyloid β‐Peptide in Patients with Alzheimer's Disease

J. Growdon, W. Oertel, I. Heuser, 2000, Annals of the New York Academy of Sciences.

Talsaclidine (WAL 2014 FU), a muscarinic M1 receptor agonist for the treatment of Alzheimer's disease

M. Wienrich, A. Ceci, W. Gaida, 2002 .

Differences in psychic performance with guanfacine and clonidine in normotensive subjects.

H. M. Brecht, J. Kugler, A. Raschig, 1980, British journal of clinical pharmacology.

Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42 in patients with Alzheimer's disease

W. Oertel, H. Hampel, R. Nitsch, 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man.

M. Wienrich, M Wienrich, R Hammer, 2001, Life sciences.

A Multicentre Trial with Pindolol

D. Welzel, J. Rosenthal, A. Raschig, 2023 .

Treatment of Hypertension with a Beta‐Adrenoceptor Blocker

D. Welzel, J. Rosenthal, A. Raschig, 1979, The British journal of clinical practice.

Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.

T. Lehr, C. Kloft, D. Trommeshauser, 2007, British journal of clinical pharmacology.